Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1 / 2 Double-blind, Randomized, Sham-controlled Dose Escalation Study to Determine Safety and Tolerability of Single Dose Intrathecal ST-503 Gene Therapy for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

NCT06980948 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.

NCT NCT06980948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06980948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1 / 2 Double-blind, Randomized, Sham-controlled Dose Escalation Study to Determine Safety and Tolerability of Single Dose Intrathecal ST-503 Gene Therapy for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
Lead sponsor
Sangamo Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 4, 2025
Completion date
July 31, 2028
Enrollment
27 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic neuropathic pain